Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications [0.03%]
针对PI3K/Akt/mTORC1通路不同节点的everolimus与alpelisib在激素受体阳性HER2阴性晚期乳腺癌中的疗效和临床意义比较研究
Claudio Vernieri,Francesca Corti,Federico Nichetti et al.
Claudio Vernieri et al.
Background: The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2- mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mT...
Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast [0.03%]
导管原位癌的免疫微环境与侵袭性乳腺癌的比较
Milim Kim,Yul Ri Chung,Hyun Jeong Kim et al.
Milim Kim et al.
Background: The immune microenvironment in ductal carcinoma in situ (DCIS) and its significance are not well established. This study was conducted to evaluate the immune microenvironment of DCIS including the composition ...
Comparative Study
Breast cancer research : BCR. 2020 Mar 26;22(1):32. DOI:10.1186/s13058-020-01267-w 2020
High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer [0.03%]
原发性肿瘤中高表达肝细胞生长因子预示男性乳腺癌患者较好的总生存期
Si-Qi Qiu,Johan van Rooijen,Hilde H Nienhuis et al.
Si-Qi Qiu et al.
Background: Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight ma...
Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens [0.03%]
弥漫性光学光谱成像揭示了早期内乳腺肿瘤对最小有效剂量和最大耐受剂量方案的血流动力学反应的区别
Anup Tank,Hannah M Peterson,Vivian Pera et al.
Anup Tank et al.
Background: Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to r...
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies [0.03%]
帕博西尼减量后激素受体阳性/人类表皮生长因子受体2阴性晚期乳腺癌患者的血液学不良事件：来自随机Ⅱ期和Ⅲ期临床研究的汇总分析
Johannes Ettl,Seock-Ah Im,Jungsil Ro et al.
Johannes Ettl et al.
Background: Palbociclib improves outcomes for women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC). Dose reductions are recommended for the manageme...
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis [0.03%]
Correction to: ESR1突变在新诊断的转移性和局部区域复发的内分泌治疗乳腺癌中频繁出现，并预示着较差的预后
Adi Zundelevich,Maya Dadiani,Smadar Kahana-Edwin et al.
Adi Zundelevich et al.
After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients' codes are listed, was cropped by mistake so the patients 1-8 are repeated.
Published Erratum
Breast cancer research : BCR. 2020 Mar 12;22(1):28. DOI:10.1186/s13058-020-01265-y 2020
MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth [0.03%]
miR-7通过抑制XIST调节miR-92b/Slug/ESA轴以降低BCSC亚群并抑制肿瘤生长
Miao Li,Meng Pan,Chengzhong You et al.
Miao Li et al.
Background: Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through...
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers [0.03%]
对：减瘤输卵管卵巢切除术、自然绝经与乳腺癌风险：BRCA1和BRCA2基因突变携带者国际前瞻性队列研究的更正
Nasim Mavaddat,Antonis C Antoniou,Thea M Mooij et al.
Nasim Mavaddat et al.
After publication of the original article [1], we were notified that columns in Table 2 were erroneously displayed.
Published Erratum
Breast cancer research : BCR. 2020 Feb 26;22(1):25. DOI:10.1186/s13058-020-01259-w 2020
Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort [0.03%]
循环27-羟基胆固醇与EPIC-海德堡队列乳腺组织CYP27A1、CYP7B1、LXR-β和ERβ表达情况的研究结果
Charlotte Le Cornet,Britta Walter,Disorn Sookthai et al.
Charlotte Le Cornet et al.
Background: Experimental and epidemiological studies demonstrate a role for 27-hydroxycholesterol (27HC) in breast cancer development, though results are conflicting. Cholesterol 27-hydroxylase (CYP27A1) and oxysterol 7-a...